News | April 29, 2013

Simple Home Test Can Halve the Risk of Stroke for Patients on Warfarin

UK Blood Clots Teststing Wafarin Self Monitoring

April 29, 2013 — A simple self-monitoring test could reduce the risk of stroke by half in thousands of people in the United Kingdom who currently take warfarin to prevent blood clots. Better access to self-monitoring of international normalized ratio (INR) levels, which measures how long it takes blood to form a clot, could also lower mortality rates by nearly two fifths,[1] reduce the number of complications and has the potential to save the U.K. National Health Service (NHS) around £62 million a year,[2] a group of members of  parliament (MPs), patients and charities stated this week.

Speaking in Parliament, Virendra Sharma, MP and member of the Health Select Committee, said that many patients who take the anticoagulant warfarin were not benefitting from self-monitoring through either a lack of awareness or issues around access. He stated that "There are more than 1.2 million people in the U.K. on warfarin[3,4] but fewer than 2 percent of them benefit from self-monitoring."[5]

He went on to say: "If more patients are able to choose to self-monitor, it would improve the quality of their care and create savings for the NHS. We need to see more opportunities for people to discuss the option of self-monitoring with their GP. So today we are encouraging patients and their families to write to their local MPs asking for self-monitoring technology to be made available on NHS prescription and to register their support for the ACSMA campaign atwww.acsma.org.uk."

Warfarin is used to reduce the risk of blood clots in conditions such as atrial fibrillation, deep vein thrombosis, pulmonary embolism and in people with mechanical heart valves.

This week at the House of Commons, the AntiCoagulation Self-Monitoring Alliance (ACSMA) launched a new campaign to increase patient access via prescription to self-monitoring technology for those on longterm warfarin treatment. ACSMA comprises four of the U.K.'s leading charities and patient groups — AntiCoagulation Europe (ACE); the Children's Heart Federation; the Atrial Fibrillation Association (AF Association) and; the For Mechanical Heart Valve Support Group. Healthcare company Roche is also part of the alliance.

References:

1. Heneghan C, et al. "Self-monitoring of oral anticoagulation: a systematic review and meta-analysis." Lancet 2006; 367(9508): 404-11.

2. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al. "Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling [online]." Health Technol. Assess. 2007 Oct; 11(38): iii-iv, ix-66.

3. Gardiner, et al. "Patient self-testing is a reliable and acceptable alternative to laboratory monitoring." Br J Haem 2004; 128: 242-47.

4. Office for National Statistics 2008. Accessed 16 June 2011.

5. Data on file

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Overlay Init